260 related articles for article (PubMed ID: 7698086)
1. Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility.
Daly AK; Cholerton S; Armstrong M; Idle JR
Environ Health Perspect; 1994 Nov; 102 Suppl 9(Suppl 9):55-61. PubMed ID: 7698086
[TBL] [Abstract][Full Text] [Related]
2. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes.
Longuemaux S; Deloménie C; Gallou C; Méjean A; Vincent-Viry M; Bouvier R; Droz D; Krishnamoorthy R; Galteau MM; Junien C; Béroud C; Dupret JM
Cancer Res; 1999 Jun; 59(12):2903-8. PubMed ID: 10383153
[TBL] [Abstract][Full Text] [Related]
3. [Interindividual differences in efficacy and toxicity induced by therapeutic drugs and xenobiotics in relation to genetic polymorphisms in xenobiotic metabolizing enzymes].
Ozawa S
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1998; (116):69-81. PubMed ID: 10097514
[TBL] [Abstract][Full Text] [Related]
4. Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes.
Thier R; Brüning T; Roos PH; Rihs HP; Golka K; Ko Y; Bolt HM
Int J Hyg Environ Health; 2003 Jun; 206(3):149-71. PubMed ID: 12872524
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility--a review.
Raunio H; Husgafvel-Pursiainen K; Anttila S; Hietanen E; Hirvonen A; Pelkonen O
Gene; 1995 Jun; 159(1):113-21. PubMed ID: 7607565
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity.
Wormhoudt LW; Commandeur JN; Vermeulen NP
Crit Rev Toxicol; 1999 Jan; 29(1):59-124. PubMed ID: 10066160
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetic profile of xenobiotic enzyme metabolism in survivors of the Spanish toxic oil syndrome.
Ladona MG; Izquierdo-Martinez M; Posada de la Paz MP; de la Torre R; Ampurdanés C; Segura J; Sanz EJ
Environ Health Perspect; 2001 Apr; 109(4):369-75. PubMed ID: 11335185
[TBL] [Abstract][Full Text] [Related]
8. [Genetic polymorphisms in xenobiotic metabolizing enzymes as a determinant of susceptibility to environmental mutagens and carcinogens in humans].
Ozawa S
Yakugaku Zasshi; 1997 Nov; 117(10-11):895-909. PubMed ID: 9414599
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous genotyping of nine polymorphisms in xenobiotic-metabolizing enzymes by multiplex PCR amplification and single base extension.
Knaapen AM; Ketelslegers HB; Gottschalk RW; Janssen RG; Paulussen AD; Smeets HJ; Godschalk RW; Van Schooten FJ; Kleinjans JC; Van Delft JH
Clin Chem; 2004 Sep; 50(9):1664-8. PubMed ID: 15331501
[No Abstract] [Full Text] [Related]
10. Polymorphic enzymes of xenobiotic metabolism as modulators of acquired P53 mutations in bladder cancer.
Brockmöller J; Kaiser R; Kerb R; Cascorbi I; Jaeger V; Roots I
Pharmacogenetics; 1996 Dec; 6(6):535-45. PubMed ID: 9014203
[TBL] [Abstract][Full Text] [Related]
11. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer.
Nebert DW; McKinnon RA; Puga A
DNA Cell Biol; 1996 Apr; 15(4):273-80. PubMed ID: 8639263
[TBL] [Abstract][Full Text] [Related]
12. Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients.
Roots I; Brockmöller J; Drakoulis N; Loddenkemper R
Clin Investig; 1992; 70(3-4):307-19. PubMed ID: 1355678
[TBL] [Abstract][Full Text] [Related]
13. Xenobiotic-metabolizing enzymes and cancer risk: correspondence between genotype and phenotype.
Pelkonen O; Raunio H; Rautio A; Lang M
IARC Sci Publ; 1999; (148):77-88. PubMed ID: 10493250
[TBL] [Abstract][Full Text] [Related]
14. Frequency of mutant CYP1A1, NAT2 and GSTM1 alleles in normal Indians and Malays.
Zhao B; Lee EJ; Wong JY; Yeoh PN; Gong NH
Pharmacogenetics; 1995 Oct; 5(5):275-80. PubMed ID: 8563767
[TBL] [Abstract][Full Text] [Related]
15. CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma.
Gajecka M; Rydzanicz M; Jaskula-Sztul R; Kujawski M; Szyfter W; Szyfter K
Mutat Res; 2005 Jul; 574(1-2):112-23. PubMed ID: 15914211
[TBL] [Abstract][Full Text] [Related]
16. Polymorphism of drug-metabolizing enzymes in relation to individual susceptibility to industrial chemicals.
Nakajima T; Aoyama T
Ind Health; 2000 Apr; 38(2):143-52. PubMed ID: 10812837
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of the polymorphic alleles of genes encoding phase 1 and phase 2 detoxication enzymes in patients with endometriosis].
Ivashchenko TE; Shved NIu; Kramareva NA; Aĭlamazian EK; Baranov VS
Genetika; 2003 Apr; 39(4):525-9. PubMed ID: 12760253
[TBL] [Abstract][Full Text] [Related]
18. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk.
Brockmöller J; Cascorbi I; Kerb R; Roots I
Cancer Res; 1996 Sep; 56(17):3915-25. PubMed ID: 8752158
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphism of enzymes involved in xenobiotic metabolism and the risk of colorectal cancer.
Kiyohara C
J Epidemiol; 2000 Sep; 10(5):349-60. PubMed ID: 11059519
[TBL] [Abstract][Full Text] [Related]
20. Relationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancer.
Suzuki S; Muroishi Y; Nakanishi I; Oda Y
J Gastroenterol; 2004; 39(3):220-30. PubMed ID: 15064998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
